Skip to main content
Clinical Trials/NCT03140319
NCT03140319
Unknown
Phase 1

Autologous Transplantation of Cultured Fibroblast for Correction of Nasolabial Folds

SCARM Institute, Tabriz, Iran1 site in 1 country50 target enrollmentDecember 10, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Nasolabial Folds
Sponsor
SCARM Institute, Tabriz, Iran
Enrollment
50
Locations
1
Primary Endpoint
Correction of Nasolabial
Last Updated
5 years ago

Overview

Brief Summary

The study evaluated the safety and efficacy of the Autologous cultured fibroblast for correction of Nasolabial folds and inhibition of skin aging

Detailed Description

Autologous cultured fibroblast which is obtain from the patient's normal skin is harvested and expanded in an in vitro. Biopsies samples are obtained from the behind of the patient's ear as a source of fibroblasts, then fibroblast cells isolated and expanded through cell culture, and used for the correction of Nasolabial folds, deep wrinkles of the forehead. Prior to final packaging, cell viability is assessed to be at least 85%

Registry
clinicaltrials.gov
Start Date
December 10, 2020
End Date
December 26, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
SCARM Institute, Tabriz, Iran
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Available and willing to attend all follow-up visits.
  • Age \> 18 years.
  • Able and willing to give informed consent

Exclusion Criteria

  • Known allergy or sensitivity to any cellular products
  • The subject has received a soft tissue augmentation to the area to be treated within the last 6 months.
  • Subject is unwilling to forgo any cosmetic augmentation procedures for the duration of the study.
  • The subject has received autologous fat transfer in the last 6 months.
  • Subject is suffering from facial Kaposi's sarcoma.
  • The subject has active skin diseases or inflammation on or near the area of injection
  • positive HIV, hepatitis B virus (HBV), hepatitis C virus (HCV)

Outcomes

Primary Outcomes

Correction of Nasolabial

Time Frame: 6 months after transplantation

Evaluate the correction of skin changes after transplantation of autologous fibroblasts by medical examination

Study Sites (1)

Loading locations...

Similar Trials